U.S. Markets closed
  • S&P Futures

    3,929.75
    +7.25 (+0.18%)
     
  • Dow Futures

    32,006.00
    +90.00 (+0.28%)
     
  • Nasdaq Futures

    13,319.50
    +17.50 (+0.13%)
     
  • Russell 2000 Futures

    2,297.90
    +12.80 (+0.56%)
     
  • Crude Oil

    63.37
    +0.15 (+0.24%)
     
  • Gold

    1,794.30
    -3.60 (-0.20%)
     
  • Silver

    28.13
    +0.20 (+0.72%)
     
  • EUR/USD

    1.2171
    +0.0003 (+0.0243%)
     
  • 10-Yr Bond

    1.3890
    +0.0270 (+1.98%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4142
    +0.0000 (+0.0028%)
     
  • USD/JPY

    106.0090
    +0.1270 (+0.1199%)
     
  • BTC-USD

    50,366.39
    -24.21 (-0.05%)
     
  • CMC Crypto 200

    1,004.86
    -10.06 (-0.99%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,156.48
    +484.78 (+1.63%)
     

CanSinoBIO says filed application in China for COVID-19 vaccine approval

  • Oops!
    Something went wrong.
    Please try again later.

Feb 24 (Reuters) - CanSino Biologics Inc said on Wednesday it has filed an application in China to seek approval of its COVID-19 vaccine after global trials of the shot showed positive results.

CanSino said the interim analysis of data from its multi-country trial showed that its candidate, known as Ad5-nCoV, has an efficacy rate of 65.28% at preventing all symptomatic cases and 90.07% at preventing severe disease 28 days after a single dose has been given. (Reporting by Anushka Trivedi in Bengaluru; Editing by Christian Schmollinger)